Keros Therapeutics Inc (KROS)

SG&A Expenses

$8.61M

Quarterly · Period ending: · USD

KROS logo

KROS SG&A Expenses

Latest reported$8.61M
KROS Quarterly SG&A Expenses ($491.00K → $8.61M)
High-resolution chart · PNG

KROS sg&a expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Keros Therapeutics Inc SG&A Expenses — Quarterly (USD)
Period endingSG&A Expenses (USD)
8,606,000
10,147,000
11,743,000
10,127,000
14,482,000
10,497,000
10,665,000
9,820,000
9,961,000
10,308,000
9,105,000
8,597,000
8,803,000
7,778,000
7,093,000
6,937,000
7,447,000
6,048,000
5,731,000
5,365,000
5,658,000
4,274,000
3,617,000
3,553,000
3,650,000
1,977,000
1,067,000
972,000
654,000
491,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.